Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (13052)	9/20/2004 12:24:49 PM
From: Icebrg	Read Replies (2) \| Respond to of 52153

As far as I remember the name was changed at FDA's request from Maxamine in order to avoid a potential naming conflict with Maxipime. Erik

To: tuck who wrote (13052)	9/20/2004 1:46:03 PM
From: Biomaven	Respond to of 52153

Didn't you once quote some hedgie as saying "short clinical trials?" Not actually a hedgie - actually a CEO of a very large biotech fund that primarily invests in private biotechs. Not sure if he was tongue-in-cheek or not. That's not to say the majority of trials fail - but certainly the price haircut when they do typically exceeds the upside when they don't. Certainly be interesting to see a systematic study. But you really need to do this only on trials where the result isn't already pretty much known - for example the 57th Indiplon trial with some dosage variant doesn't really belong in the same class as this Ceplene trial. Peter